Extreme price hikes for a handful of pharmaceuticals in recent years have severely soured public sentiment toward the industry. Drugmakers are pushing back with a public relations campaign to highlight the new treatments they bring to the table. But industry watchers say what they might need instead is more transparency and perspective, according to the cover story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.